ADVERTISEMENT

Anand Rathi: Indian Pharma Market’s Growth Eases To 1%  In November As Chronic Sales Contract

Anand Rathi: Indian Pharma Market’s Growth Eases To 1%  In November As Chronic Sales Contract

Holding colourful capsules strips (Photograph Bloomberg)
Holding colourful capsules strips (Photograph Bloomberg)

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Anand Rathi Report

The Indian Pharma Market grew just 1% in November 2020. During the past six months cardiac therapy had been growing in high teens; contracting now to single digits.

Overall, sales of chronic brands grew 3% while acute therapies continue to struggle, their sales being down 1%.

Volume decline for the industry continued in Nov-20. It was down 7% while blended price growth was 5%, with new-product growth of 3%.

Click on the attachment to read the full report:

Anand Rathi IPM Sector Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.